These data indicate that PLAU1 and MMP1 are identified as biomarkers for accurately predicting the prognosis and performing the diagnosis of HNSCC; thus, they may serve as potential targets for clinical therapies to treat HNSCC. Here, MMP1 is linked to head and neck squamous cell carcinoma.